Opinion|Videos|January 31, 2024
Hemophilia A Treatment Factors and Outcomes
Understand key factors influencing hemophilia A treatment decisions and explore the impact of prophylactic vs on-demand therapy on efficacy, safety, and patient outcomes, including joint health, bleeding episodes, and quality of life in severe cases.
Episodes in this series
This is a video synopsis/summary of an Insights involving Allison Wheeler, MD.
Wheeler delves into the multifaceted considerations when determining the appropriate treatment for hemophilia A, emphasizing the importance of patient-specific factors. She starts with evaluating baseline factor activity and disease severity, underlining the need to adapt treatment to individual needs. Early prophylactic therapy initiation, historically around 1 year of life, has been a standard for severe disease. The evolving landscape now includes nonfactor products, allowing for more flexibility in administration, catering to patient preferences.
Addressing prophylactic versus on-demand therapy for severe hemophilia A, Wheeler unequivocally advocates for prophylaxis, referencing Marilyn Manco-Johnson’s influential work showing improved joint outcomes. The standard of care involves initiating prophylactic treatment early, with advancements like factor VIII mimetic enabling earlier intervention. Wheeler emphasizes the reduction in bleeding episodes and joint damage, and improvement in quality of life with prophylaxis. Acknowledging the impact of untreated patients experiencing daily pain and restricted joint movement, she asserts prophylactic treatment as a crucial element for enhancing patient outcomes, making it a standard of care for severe hemophilia A.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Related to this article
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Portuguese patch testing finds many chronic hand eczema cases link to allergic contact dermatitis—especially occupational exposures like methylisothiazolinone, HEMA acrylates, thiuram mix, nickel.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
These findings demonstrate substantial but variable use of community care consultations for specialty care among patients with diabetic foot ulcers within the Veterans Health Administration.
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
Trending on AJMC
1
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Switching to Subcutaneous Ocrelizumab for MS Could Free 883 Chair Hours in a Year
4
Why 4 in 5 Eligible Adults Miss Lung Cancer Screening
5